The Serum Institute of India will attempt to launch an Omicron-specific vaccine for COVID-19 after six months, Adar Poonawalla, CEO of SII said on Thursday. Talking to reporters on the sidelines of an event, he spoke there is useful data available for the Covavax vaccine.
The Pune-based Serum Institute is operating with US biotechnology major Novavax to fetch the Omicron-specific vaccine.
The World Health Organisation declared Omricron as a sub-variant of Covid-19 due to its fast transmission and infection rate. The company’s Covavax vaccine is available for those above the age of 12 in the country.
On monkeypox, Poonawalla said the need for a vaccine is ‘debatable.’ “Yes, it created a little bit of buzz when we saw the cases here. We are researching the topic and can collaborate with the Department of Biotechnology on it too. Our research is going on and we will see in six months”, he stated.